This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up
by Zacks Equity Research
HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.
HALONegative Net Change JNJPositive Net Change ARGXPositive Net Change LQDAPositive Net Change
biotechs earnings
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
by Zacks Equity Research
IMCR incurs wider-than-expected Q2 loss. However, revenues beat as sole drug Kimmtrak sales rise 18.3% year over year on higher U.S. and international sales.
IMCRNegative Net Change RGENNegative Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs earnings
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
by Zacks Equity Research
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
OCGNPositive Net Change RGENNegative Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
by Zacks Equity Research
IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.
IRWDNegative Net Change AZNPositive Net Change ABBVPositive Net Change LQDAPositive Net Change
biotechs earnings
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
by Zacks Equity Research
BioMarin stock rises on Q2 sales beat and raises 2026 outlook, highlighting strong Voxzogo growth, Amicus additions and momentum in key therapies.
BMRNPositive Net Change SNYPositive Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
by Zacks Equity Research
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
PBYINegative Net Change ALTNegative Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
by Zacks Equity Research
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
NTLAPositive Net Change REGNPositive Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
by Zacks Equity Research
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
INSMPositive Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs earnings medical
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
by Zacks Equity Research
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
XENEPositive Net Change NBIXPositive Net Change LQDAPositive Net Change HRMYPositive Net Change
biotechs
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
by Zacks Equity Research
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
GILDNegative Net Change
biotechnology biotechs earnings pharmaceuticals